ISS Joins Glass Lewis in Urging Parkland Shareholders to Vote For Meaningful Change
GRAND CAYMAN, Cayman Islands--(BUSINESS WIRE)--Apr 28, 2025--
Simpson Oil Limited ('Simpson Oil', 'we' or 'our'), the largest shareholder of Parkland Corporation ('Parkland' or the 'Company'), holding 19.8% of the outstanding common shares, today announced that Institutional Shareholder Services Inc. ('ISS') has joined Glass, Lewis & Co. ('Glass Lewis') in recommending that Parkland shareholders support significant change by voting for six of its nine director nominees at the Company's Annual General Meeting (the 'Meeting' or the 'AGM') to be held on May 6, 2025.
ISS has recommended that shareholders vote the GOLD proxy card to elect Monty Baker, Michael Christiansen, Chris Folan, Brian Gibson, Darcy Morris, and Karen Stuckey to the Board of Directors (the 'Board').
Both ISS and Glass Lewis delivered scathing assessments of the current Board and its prolonged track record of underperformance and value destruction. In recommending the GOLD proxy card, ISS noted:
'…it is paradoxical that the board would concede a compelling case for change, as evidenced by the planned resignation of the company's CEO, commencement of a strategic review, and recommendation for three dissident nominees, while asserting that PKI (and not shareholders) should control how many, and which dissident nominees should be elected.'
On governance, ISS criticized the Board's handling of CEO succession, noting:
'The board's actions with respect to CEO succession in the last year are troubling in view of the fact that little evidence exists robust CEO succession planning measures were implemented, including an evaluation of external CEO prospects, during a pivotal year for CEO performance.'
Both proxy advisors also flagged 'grave' governance concerns, citing entrenched behaviors and persistent gamesmanship. ISS concluded:
'In short, the board has displayed a troubling pattern of decision-making aimed at thwarting the dissident. This has been reflected in the board's treatment of the dissident, in the board's persistent gamesmanship, and in the board's failure to proactively address leadership and other critical matters. These and other decisions havecome at a steep cost to shareholders.'
ISS also underscored that responsibility for these governance failures extends to key members of the current Board:
'[Chair Michael] Jennings served alongside [Richard] Hookway and [Nora] Duke on the [governance and ethics] committee over the past year, meaning that all three bear some responsibility for PKI's deficient corporate governance.'
In light of the above commentary, Simpson Oil reiterates the urgent need for wholesale change and the election of all NINE of its highly qualified nominees. Michael Jennings is clearly accountable for the reactive behaviour of the Board as a whole and its efforts to prevent Simpson Oil from exercising its basic shareholder rights—the tone comes from the top. Furthermore, with the selection of Chris Folan by both ISS and Glass Lewis, there is no justification for retaining legacy director James Neate.
Finally, given the Board's history of flawed governance practices, we caution the Company from deploying any tactics that could delay the Meeting and/or compromise the integrity of the shareholder vote.
Protect Your Investment: Vote For ALL NINE Simpson Oil Nominees
Simpson Oil reiterates that only the election of ALL NINE of its highly qualified nominees will deliver the fresh leadership, governance, and accountability shareholders deserve.
VOTE TODAY: Please ensure your GOLD form of proxy or VIF is received by the proxy voting deadline of May 1, 2025, at 5:00pm Mountain Time.
If you would like to vote shares that you hold in your Employee Share Purchase Plan (ESPP), if you have not received your Voting Instruction Form (VIF) by mail, or if you need help voting the GOLD proxy, please contact Carson Proxy, at 1-800-530-5189 (North America Toll Free), 416-751-2066 (Local and Text), or by email at [email protected].
For more information on the Simpson Oil nominees, their plan to unlock shareholder value at Parkland, and how to vote for the entire Simpson Oil slate on the GOLD Proxy Card, visit www.RefuelParkland.com. Proxy materials are also available under Parkland's SEDAR+ profile at www.sedarplus.ca, including a GOLD Proxy Card or voting instruction form.
Advisors
Blake, Cassels & Graydon LLP is serving as legal counsel. Longacre Square Partners is serving as strategic advisor, and Carson Proxy is serving as proxy solicitor.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250428370934/en/
CONTACT: Media Enquiries
Longacre Square Partners
Amy Freedman / Andy Radia
[email protected]
Shareholder Enquiries
Carson Proxy
Christine Carson, 416-804-0825
[email protected]
KEYWORD: CARIBBEAN CAYMAN ISLANDS NORTH AMERICA CANADA
INDUSTRY KEYWORD: ENERGY PROFESSIONAL SERVICES OIL/GAS FINANCE
SOURCE: Simpson Oil Limited
Copyright Business Wire 2025.
PUB: 04/28/2025 05:20 PM/DISC: 04/28/2025 05:21 PM
http://www.businesswire.com/news/home/20250428370934/en
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Palantir-Backed Voyager Rockets Above $31 IPO Price
Voyager Technologies kicks off trading on the NYSE after pricing its IPO at $31above its marketed $26$29 rangeraising $382.8 million at a $1.9 billion market cap in what Wall Street sees as a litmus test for space-sector stocks. Backed by Palantir Technologies (NASDAQ:PLTR) and Lockheed Martin (NYSE:LMT), Voyager's debut follows Circle's blockbuster listing and precedes Chime's IPO, spotlighting investor appetite for high-growth tech niches. Founded in Colorado, Voyager specializes in defense and commercial space technologies, with NASA as its largest customer under a $217.5 million contract to design the Starlab space station set to succeed the ISS around 2030. In 2024, Voyager posted $144.2 million in sales26% of which came from NASAand saw revenue grow 6% last year and 14% in Q1 2025, though it reported a $65.6 million net loss as it scales operations. Management expanded the share sale to 12.35 million shares to meet demand, tapping a broad investor base eager for exposure to orbital infrastructure ahead of U.S. defense initiatives like the proposed Golden Dome missile-defense shield. Investors should care because Voyager's trading performance will gauge market enthusiasm for space plays amid a wave of tech IPOs, and its strong NASA ties provide a steady revenue pillar even as profitability remains a longer-term goal. Investors will watch VOYG's first-day trading action and future earnings reports for signs that government contracts and rising commercial space investments can drive sustained growth and narrow net losses. This article first appeared on GuruFocus.
Yahoo
7 hours ago
- Yahoo
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of Directors David Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and Corporate Secretary, and Jarrad Aguirre, MD, MBA as Senior Vice-President of Medical Affairs SOUTH SAN FRANCISCO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced the appointment of Mark J. Bachleda, PharmD, MBA as an independent member of the Board of Directors, David Shook, MD as Chief Medical Officer, and Mark Meltz, JD as General Counsel and Corporate Secretary. These appointments, along with the appointment earlier in the year of Jarrad Aguirre, MD, MBA as Senior Vice President, Medical Affairs, further strengthen the Company's clinical and commercial capabilities. 'As Lyell prepares to move forward with two pivotal programs designed to advance LYL314 towards approval for patients with aggressive large B-cell lymphoma, we are delighted to welcome leaders who further strengthen and bring new expertise to our Board of Directors and our Executive Committee,' said Lynn Seely, MD, Lyell's President and Chief Executive Officer. 'Collectively, these new leaders have deep cell therapy expertise and highly relevant experience launching new medicines for patients. We look forward to their contributions as we continue to make progress on achieving our mission of bringing next-generation cell therapies to patients with cancer.' 'The addition of Dr. Bachleda to the Lyell Board provides us with experienced commercial leadership, including in cell therapy, at this critical time as Lyell becomes a late-stage clinical company initiating pivotal clinical trials and anticipating a commercial launch of LYL314,' said Rick Klausner, MD, Chairman of the Lyell Board of Directors. 'I could not be more pleased with the progress the company is making and am confident that our new executive leaders will ensure operational excellence as we focus on rapidly advancing LYL314, our autologous CD19/CD20 CAR T-cell therapy, to patients.' Mark J. Bachleda, PharmD, MBA appointed independent member of the Board of Directors Dr. Bachleda is currently the Chief Executive Officer and a member of the Board of Directors of Eyconis, Inc., a biopharmaceutical company focused on developing therapeutics for eye diseases. He has served in executive leadership roles at Amgen, Juno Therapeutics, and Bristol Myers Squibb (BMS), and, most recently, he was Chief Commercial Officer at Galera Therapeutics. Prior to joining Galera, he served as Vice President & U.S. Business Unit Head of the CAR T-cell therapy franchise at BMS, a role he held previously at Celgene Corporation before its acquisition by BMS. Prior to this, he was Vice President, Sales & Account Management at Juno when it was acquired by Celgene. His experience includes a 15-year career at Amgen in the U.S. and international roles of increasing responsibility up to Country President & General Manager of Amgen Czech Republic. Earlier in his career, he held positions at Pfizer, Inc., and Johnson & Johnson. Dr. Bachleda is a registered pharmacist and received his PharmD degree from the University of Illinois at Chicago. He completed a post-doctoral fellowship in health policy and economics at Thomas Jefferson University and earned MBA degrees from both Columbia University and the University of California, Berkeley. David Shook, MD appointed Chief Medical Officer Dr. Shook is an early pioneer of cell therapy and remains a practicing pediatric oncologist and transplant physician. Prior to Lyell, Dr. Shook was Chief Medical Officer and Head of Research and Development at Nkarta where he was responsible for leading the clinical development of multiple CAR NK cell product candidates for oncology. Prior to joining Nkarta, Dr. Shook held roles as Medical Director, Pediatric Cellular Therapy at AdventHealth and was Fellowship Director and a Faculty Member at St. Jude Children's Research Hospital. While at St. Jude, he conducted multiple first-in-human cell therapy trials, as well as research in the laboratory of Dario Campana, MD, PhD where he co-developed the membrane bound form of interleukin-15. He earned an MD from The Johns Hopkins University School of Medicine and a BS from Purdue University. Mark Meltz, JD appointed General Counsel and Corporate Secretary Mr. Meltz is an accomplished legal and business executive with more than two decades of experience leading and advising life sciences, technology and emerging growth companies. Prior to joining Lyell, Mr. Meltz was Chief Operating Officer and General Counsel of Kinnate Biopharma Inc., a clinical stage precision oncology company, through its sale to XOMA Corporation. Before Kinnate, he was Senior Vice President and General Counsel of Audentes Therapeutics through its sale to Astellas Pharma. Mr. Meltz also was previously Executive Vice President and Chief Business Development and Legal Officer at PaxVax through its sale to Emergent BioSolutions. Earlier in his career, Mr. Meltz was Associate General Counsel at Biogen and Head of Legal for North America at Novartis in its Vaccines & Diagnostics division. Mr. Meltz has supported multiple commercial launches at PaxVax, Biogen and Novartis. He earned a BA with Departmental Honors in Psychology from Yale University and a JD, Magna Cum Laude, from Boston College Law School. Jarrad Aguirre, MD, MBA appointed Senior Vice President, Medical Affairs Dr. Aguirre joined Lyell as Senior Vice President, Medical Affairs in January 2025. Prior to Lyell, Dr. Aguirre was Co-Founder and Chief Executive Officer of Miga Health, a digital health company focused on heart health, through its sale to Bitterroot Bio. Before Miga Health, Dr. Aguirre served in leadership roles at Myovant Sciences, most recently as Head of Corporate Strategy. Dr. Aguirre earned an MD and an MBA from Stanford University, an MPhil in Medical Anthropology from the University of Oxford as a Rhodes Scholar, and a BS in Biology from Yale University. About Lyell Immunopharma, Inc. Lyell is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to endow CAR T cells with attributes needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. To learn more, please visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: the performance of the Company's additions to its leadership team and Board of Directors, including the anticipated benefits of expanded strength of the Company's clinical and commercial capabilities; the continued clinical progress and anticipated commercial launch of the LYL314 trials; Lyell's anticipated progress, business plans, business strategy and clinical trials; Lyell's advancement of its pipeline, technology platform and research, development and clinical capabilities; the potential clinical benefits and therapeutic potential of Lyell's product candidates; and other statements that are not historical fact. These statements are based on Lyell's current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: the ability to retain the continued service of its key personnel; the complexity of manufacturing cellular therapies, which subjects Lyell to a multitude of manufacturing risks, any of which could substantially increase our costs, delay Lyell's programs or limit supply of Lyell's product candidates; the effects of macroeconomic conditions, including the effects of disruption between the U.S. and its trading partners due to tariffs or other policies, any geopolitical instability and actual or perceived changes in interest rates and economic inflation; Lyell's ability to initiate or progress clinical trials on the anticipated timelines, if at all; Lyell's limited experience as a company in enrolling and conducting clinical trials, and lack of experience in completing clinical trials; the nonclinical profiles of Lyell's product candidates or technology not translating in clinical trials; the potential for results from clinical trials to differ from nonclinical, early clinical, preliminary or expected results; significant adverse events, toxicities or other undesirable side effects associated with Lyell's product candidates; the significant uncertainty associated with Lyell's product candidates ever receiving any regulatory approvals; Lyell's ability to obtain, maintain or protect intellectual property rights related to its product candidates; implementation of Lyell's strategic plans for its business and product candidates; the sufficiency of Lyell's capital resources and need for additional capital to achieve its goals; and other risks, including those described under the heading 'Risk Factors' in Lyell's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Securities and Exchange Commission on May 13, 2025. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law. Contact: Ellen RoseSenior Vice President, Communications and Investor Relationserose@ in to access your portfolio
Yahoo
7 hours ago
- Yahoo
Oasis Intends to Vote Against Kyocera's Top Management at the Upcoming AGM
*Kyocera has been facing chronic underperformance, with its stock price remaining depressed over the long-term and profitability continuing to deteriorate sharply *Although Kyocera has announced certain management reform initiatives, they fall far short of the necessary fundamental changes needed to transform the Company *On May 14, Oasis released a "Seven-Point Plan" calling for more substantive reforms at Kyocera, including the acceleration of non-core business divestitures and improvements to the Company's inefficient capital structure *However, Kyocera has so far failed to address the "Seven Point Plan" and has demonstrated little commitment to genuine transformation *In its latest results, Kyocera achieved an ROE of just 0.8% *Oasis will vote against the reappointment of Chairman Yamaguchi and President Tanimoto at the upcoming AGM, holding them accountable for the underperformance and poor capital allocation *Both ISS and Glass Lewis have recommended to vote against the reappointment of Kyocera Chairman Yamaguchi, and ISS additionally recommends voting against President Tanimoto More information available at HONG KONG, June 11, 2025--(BUSINESS WIRE)--Oasis Management Company Ltd. ("Oasis") is manager to funds that beneficially own shares in Kyocera Corporation (6971 JP) ("Kyocera" or the "Company"). Oasis has adopted the Japan FSA's "Principles of Responsible Institutional Investors" (a.k.a. the Japan Stewardship Code) and in line with those principles, Oasis monitors and engages with its investee companies. At its May 14, 2025 earnings call, Kyocera reported on the progress of its management reforms. The Company appeared to acknowledge its past mistakes and expressed an intention to take the first step toward change. Specifically, Kyocera recognized the inefficiencies caused by the dispersal of management resources due to diversification and announced its policy to restructure its business portfolio in order to focus on its core strengths. However, like many shareholders and market participants, Oasis remains highly skeptical of Kyocera's commitment and ability to execute meaningful change especially in light of its modest plans and continued commitment to manufacturing solar panels and telecommunication devices. Moreover, underperformance against its management targets has become the norm. Since the fiscal year ended March 2020, Kyocera has exceeded its operating profit targets only once. This track record raises serious concerns about the current management team's ability to formulate and execute plans, casting significant doubt on whether they can even implement the current, modest reform plan. The latest earnings briefing further highlighted weak progress. Although Kyocera announced plans to exit JPY200 billion worth of non-core businesses, only JPY7.3 billion has been announced so far. This year's forecast includes just a JPY10 billion revenue reduction from exits. Kyocera's capital policy also remains insufficient. Although the Company has announced "Future Reduction Plan" to lower cross-shareholdings to below 20% of net assets, it has yet to provide a clear timeline for achieving this goal. Shareholders' dissatisfaction is growing. Approval for the Company's president at the AGM has dropped from 96% in 2015 to just 65% in 2023. ISS and Glass Lewis have once again recommended voting against the reappointment of Kyocera's Chairman, Mr. Yamaguchi. ISS has also recommended voting against President, Mr. Tanimoto, citing continued underperformance in ROE and capital misallocation. Oasis also believes that the top management is responsible for Kyocera's weak performance and therefore intends to vote against the reappointment of both individuals. Amid growing pressure from shareholders, Kyocera announced plans to reduce the cap on board directors from 20 to 12. At the same time, the Company also plans to increase the number of internal directors -- a move that runs against the broader efforts by many Japanese companies to strengthen board independence thereby decreasing the percentage of independent directors. In order for Kyocera to achieve genuine transformation and resolve its excessive diversification and inefficient capital structure, Oasis urges the full implementation of the following Seven-Point Plan: Divest non-core businesses amounting to over JPY660 billion of revenue. Exit the Organic Packages to prevent further losses. Restructure its KAVX subsidiary to achieve higher margins in line with peers. Stop losses by halting investment into GaN and millimeter-wave technologies which have little potential to produce material returns. Focus on its core business such as ceramics to capture untapped opportunities. Commit to aggressive M&A to reinforce core businesses. Announce a buyback program of JPY1 trillion over the next four years, amounting to approximately 37% of the Company. By implementing this plan, we believe that the stock could see an upside of over +100% from current levels. Seth Fischer, Founder & Chief Investment Officer of Oasis, said: "Kyocera's excessive diversification has long prevented it from realizing its full potential. The Company continues to support underperforming businesses while failing to prioritize investment and growth opportunities within its best businesses such as ceramics packaging, and the automotive and semiconductor sectors. With cross-shareholdings still accounting for 53% of its net assets and an ROE of just 0.8%, the time for meaningful change is now. Management needs to address the twin problems of over-diversification and over-capitalization of its balance sheet by exiting underperforming businesses, leaning into its best growth opportunities, and taking a much more ambitious stance on unwinding cross-shareholdings to improve returns on capital. Kyocera needs brave, large steps forward to achieve these goals. The current half measures are not enough." Full details can be viewed at All stakeholders are encouraged to contact Oasis at info@ *** Oasis Management Company Ltd. manages private investment funds focused on opportunities in a wide array of asset classes across countries and sectors. Oasis was founded in 2002 by Seth H. Fischer, who leads the firm as its Chief Investment Officer. More information about Oasis is available at Oasis has adopted the Japan FSA's "Principles for Responsible Institutional Investors" (a.k.a. the Japan Stewardship Code) and, in line with those principles, Oasis monitors and engages with our investee companies. The information and opinions contained in this press release (referred to as the "Document") are provided by Oasis Management Company ("Oasis") for informational or reference purposes only. The Document is not intended to solicit or seek shareholders to, jointly with Oasis, acquire or transfer, or exercise any voting rights or other shareholder's rights with respect to any shares or other securities of a specific company which are subject to the disclosure requirements under the large shareholding disclosure rules under the Financial Instrument and Exchange Act. Shareholders that have an agreement to jointly exercise their voting rights are regarded as Joint Holders under the Japanese large shareholding disclosure rules and they must file notification of their aggregate shareholding with the relevant Japanese authority for public disclosure under the Financial Instruments and Exchange Act. Except in the event that Oasis expressly enters into the agreement as a joint holder requiring such disclosure, Oasis does not intend to take any action triggering reporting obligations as a Joint Holder. The Document exclusively represents the opinions, interpretations, and estimates of Oasis. View source version on Contacts Media Contact For all inquiries, please contact:Taylor Hallmedia@
